Denali Therapeutics Inc.
DNLIBiotechnology
$18.94−1.97%As of Oct 30vs prior close
- Market cap
- $3B
- P/E (TTM)
- –
- From 52W high
- −30.39%
- EPS (LTM)
- -$2.93
- Revenue (LTM)
- $3.6M
- Net margin
- -14316.70%
- Dividend yield
- 0.00%
Nomior Score
42
Steady ProfileBottom 32% of the scored universe
Growth—
Quality27
Value46
Momentum64
Resilience43
Growth
$3.6Mrevenue, LTM
YE16 $0LTM $3.6M
Connections
Revenue to profitQ2 YE26
The operating loss was 3622% of revenue.
Who owns it
2funds